Chemistry:Gadoteridol

From HandWiki
Short description: Chemical compound
Gadoteridol
Gadoteridol.svg
Clinical data
Other names(10-(2-(hydroxy-κO)propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3)-κN1,κN4,κN7,κN10,κO1,κO4,κO7)-gadolinium
AHFS/Drugs.comMicromedex Detailed Consumer Information
Routes of
administration
IV
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
FormulaC17H29GdN4O7
Molar mass558.69 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Gadoteridol (INN) is a gadolinium-based MRI contrast agent, used particularly in the imaging of the central nervous system. It is sold under the brand name ProHance.[1] Gadoteridol was first approved for use in the United States in 1992.[2]

References

  1. Bracco Diagnostic Inc. (26 October 2022). "Gadoteridol (ProHance) prescribing information". DailyMed. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=778aee03-7d4c-481a-be8a-a75db0702f5a. 
  2. "Assessment of adverse reaction rates during gadoteridol-enhanced MR imaging in 28,078 patients". Radiology 259 (1): 109–16. April 2011. doi:10.1148/radiol.10100906. PMID 21248237. "Specifically, the rate of nausea (0.530%) was less than half the rate (1.4%) in clinical trials of 1251 patients, leading to FDA approval in 1992.".